Sorafenib, a systemic therapy for hepatocellular carcinoma
نویسندگان
چکیده
منابع مشابه
Sorafenib, a systemic therapy for hepatocellular carcinoma.
Hepatocellular carcinoma is a lethal disease that requires a multidisciplinary approach and management. Surgical therapy offers long-term survival; however, few patients are candidates. There has been no accepted systemic therapy for this disease until recently. This article briefly discusses the role of RAS/RAF/MEK/ERK signaling pathway in the pathogenesis of the disease and the promising role...
متن کاملTarget therapy for hepatocellular carcinoma: is sorafenib for everybody?
Hepatocellular carcinoma (HCC) is a relevant health problem, being the sixth most common cancer worldwide in terms of incidence with 626,200 new cases per year, accounting for 5.7% of all new cancer cases. Due to the poor prognosis of the disease, the number of deaths per year is almost the same as new cases (598,000), making HCC the third most common cause of cancer-related death. Prognosis an...
متن کاملSorafenib in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fi fth most common malignancy worldwide with approximately 500,000 new cases per year, ranking as the third cause of cancer deaths. Until the very recent past no systemic therapy was available for patients with advanced HCC. However, advances achieved in the understanding of the molecular cancer biology and the subsequent introduction of molecularly targete...
متن کاملSorafenib in advanced hepatocellular carcinoma.
BACKGROUND No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS In this multicenter, phase 3, double-blind, placebo-control...
متن کاملComparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
BACKGROUND Sorafenib-everolimus combination therapy may be more effective than sorafenib monotherapy for hepatocellular carcinoma (HCC). To better understand this effect, we comparatively profiled the metabolite composition of HepG2 cells treated with sorafenib, everolimus, and sorafenib-everolimus combination therapy. MATERIAL AND METHODS A 2D HRMAS 1H-NMR metabolomic approach was applied to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Hepatology
سال: 2008
ISSN: 1665-2681
DOI: 10.1016/s1665-2681(19)31886-1